Johnson & Johnson (JNJ): Price and Financial Metrics


Johnson & Johnson (JNJ): $179.46

-0.16 (-0.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

JNJ POWR Grades


  • Stability is the dimension where JNJ ranks best; there it ranks ahead of 96.16% of US stocks.
  • JNJ's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • JNJ ranks lowest in Momentum; there it ranks in the 8th percentile.

JNJ Stock Summary

  • JNJ has a higher market value than 99.74% of US stocks; more precisely, its current market capitalization is $467,326,122,403.
  • JNJ's went public 36.27 years ago, making it older than 92.84% of listed US stocks we're tracking.
  • In terms of volatility of its share price, JNJ is more volatile than only 1.84% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Johnson & Johnson, a group of peers worth examining would be UNH, JPM, WMT, BHP, and PG.
  • JNJ's SEC filings can be seen here. And to visit Johnson & Johnson's official web site, go to www.jnj.com.

JNJ Valuation Summary

  • JNJ's EV/EBIT ratio is 23.3; this is 20.48% lower than that of the median Healthcare stock.
  • Over the past 243 months, JNJ's price/sales ratio has gone down 1.
  • Over the past 243 months, JNJ's price/sales ratio has gone down 1.

Below are key valuation metrics over time for JNJ.

Stock Date P/S P/B P/E EV/EBIT
JNJ 2021-08-31 5.1 6.6 25.7 23.3
JNJ 2021-08-30 5.1 6.6 25.7 23.4
JNJ 2021-08-27 5.1 6.5 25.6 23.3
JNJ 2021-08-26 5.1 6.6 25.7 23.3
JNJ 2021-08-25 5.1 6.6 25.8 23.5
JNJ 2021-08-24 5.2 6.6 26.0 23.6

JNJ Growth Metrics

    The 5 year cash and equivalents growth rate now stands at 12.04%.
  • Its 2 year cash and equivalents growth rate is now at 6.09%.
  • Its 3 year price growth rate is now at 23.79%.
JNJ's revenue has moved up $12,919,000,000 over the prior 15 months.

The table below shows JNJ's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 93,775 23,410 20,878
2021-09-30 91,446 26,021 17,880
2021-06-30 89,190 26,114 17,767
2021-03-31 84,214 24,252 15,115
2020-12-31 82,584 23,536 14,714
2020-09-30 80,856 21,591 16,986

JNJ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • JNJ has a Quality Grade of B, ranking ahead of 92.45% of graded US stocks.
  • JNJ's asset turnover comes in at 0.52 -- ranking 78th of 682 Pharmaceutical Products stocks.
  • CBIO, CLSD, and ABBV are the stocks whose asset turnover ratios are most correlated with JNJ.

The table below shows JNJ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-10-03 0.520 0.675 0.295
2021-07-04 0.514 0.670 0.302
2021-04-04 0.498 0.662 0.273
2021-01-03 0.501 0.656 0.272
2020-09-27 0.504 0.657 0.332
2020-06-28 0.514 0.657 0.307

JNJ Price Target

For more insight on analysts targets of JNJ, see our JNJ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $187.95 Average Broker Recommendation 1.53 (Moderate Buy)

JNJ Stock Price Chart Interactive Chart >

Price chart for JNJ

JNJ Price/Volume Stats

Current price $179.46 52-week high $186.69
Prev. close $179.62 52-week low $155.72
Day low $178.60 Volume 6,896,211
Day high $181.00 Avg. volume 7,862,694
50-day MA $178.90 Dividend yield 2.52%
200-day MA $169.99 Market Cap 472.23B

Johnson & Johnson (JNJ) Company Bio


Founded in 1886, Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture, and sale of products in the healthcare field within its Consumer, Pharmaceutical and Medical Devices segments. The Consumer segment consists of skin and self-care product brand names such as Aveeno, Neutrogena, Rogaine, Tylenol, Motrin, Listerine, and Band-Aid. Johnson’s Pharmaceutical segment contains biopharma products that address immune, cardiovascular, metabolic, and infectious disease medical conditions. The Medical Device segment develops products centered around orthopedic, surgical, intervention, and vision solutions. The company has over 130,000 employees worldwide and is headquartered in New Brunswick, New Jersey. The company’s current Chief Executive Officer is Alex Gorsky.


JNJ Latest News Stream


Event/Time News Detail
Loading, please wait...

JNJ Latest Social Stream


Loading social stream, please wait...

View Full JNJ Social Stream

Latest JNJ News From Around the Web

Below are the latest news stories about Johnson & Johnson that investors may wish to consider to help them evaluate JNJ as an investment opportunity.

Johnson & Johnson given go-ahead for bankruptcy strategy on talc lawsuits

A bankruptcy court judge has upheld Johnson & Johnson's (JNJ +4.4%) request to use a bankruptcy strategy to handle 38K lawsuits related to its talc products pending against the company, The Wall Street Journal reports. The ruling by Judge Michael Kaplan of the U.S. Bankruptcy Court in Trenton, N.J., will...

Seeking Alpha | February 25, 2022

$26 billion opioid crisis settlement finalized with Johnson & Johnson, 3 drug distributors

Drug distributors McKesson, AmerisourceBergen and Cardinal Health are part of the settlement.

New York Daily News | February 25, 2022

Johnson & Johnson, Pharmaceutical Distributors Agree To $26 Billion Opioid Lawsuit Settlement

California is expected to receive $2.05 billion, while the City of Los Angeles could get "tens of millions" from the settlement.

CBS Los Angeles | February 25, 2022

Judge greenlights J&J strategy to resolve talc lawsuits in bankruptcy court By Reuters

© Reuters. The company logo for Johnson & Johnson is displayed to celebrate the 75th anniversary of the company’s listing at the New York Stock Exchange (NYSE) in New York, U.S., September 17, 2019. REUTERS/Brendan McDermid By Dietrich Knauth and Tom Hals (Reuters) -Johnson & Johnson can use the bankruptcy system to resolve multibillion-dollar litigation …

State Of Press | February 25, 2022

Dow Jones Surges As Putin Tightens Grip On Ukraine; Etsy Explodes; 3 Stocks Make Bullish Moves

The Dow Jones rallied as Vladimir Putin tightened his grip on Ukraine. Etsy stock soared on earnings, as did Block. Johnson & Johnson surged.

Investor''s Business Daily | February 25, 2022

Read More 'JNJ' Stories Here

JNJ Price Returns

1-mo -2.20%
3-mo 8.80%
6-mo 14.18%
1-year 8.86%
3-year 39.86%
5-year 61.27%
YTD 6.26%
2021 11.44%
2020 10.82%
2019 16.22%
2018 -5.13%
2017 24.43%

JNJ Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full JNJ Dividend History

Continue Researching JNJ

Want to see what other sources are saying about Johnson & Johnson's financials and stock price? Try the links below:

Johnson & Johnson (JNJ) Stock Price | Nasdaq
Johnson & Johnson (JNJ) Stock Quote, History and News - Yahoo Finance
Johnson & Johnson (JNJ) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6815 seconds.